江苏澳洋健康产业股份有限公司 关于举行 2022 年年度报告业绩说明会的通知 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 江苏澳洋健康产业股份有限公司《2022 年年度报告》全文及摘要已于 2023 年 3 月 23 日经公司第八届董事会第十次会议审议通过。《2022 年年度报告》全 文及摘要已于 2023 年 3 月 24 日刊登于巨潮资讯网站（http://www.cninfo.com.cn） 上，《2022 年年度报告摘要》同时刊登在《证券时报》上，供全体股东和投资者 查询。 为使广大投资者进一步详细了解公司年报信息，公司定于 2023 年 4 月 7 日 （星期五）15:00-17:00 在深圳证券信息有限公司提供的网上平台举行年度报告 说明会，本次年度报告说明会将采用网络远程的方式举行，投资者可登录"全景 •路演天下"（http://rs.p5w.net）参与公司年度报告说明会。 关于举行 2022 年年度报告业绩说明会的通知 证券代码：002172 证券简称：澳洋健康 公告编号：2023-18 届时公司董事长兼总经理沈学如先生，董事 ...

Group 1: Viscose Staple Fiber Business - The market consensus is optimistic about the rising price trend of viscose, and the company is confident in the development of its viscose staple fiber business [2] - The Xinjiang production base is accelerating environmental investments and acceptance, aiming for early resumption of production while phasing out outdated capacity and expanding downstream appropriately [2] Group 2: Health Industry Development - In the medical service sector, the company has established a healthcare system centered around Aoyang Hospital, with branches like Yangshe, Sanxing, and Shunkang, focusing on basic medical care and specialty services [3] - Aoyang Pharmaceutical has become one of the largest private pharmaceutical logistics companies in East China, with a modern distribution network covering the region and extending nationwide [3] - The company aims to leverage its public platform for both internal development and external expansion in the health industry, striving to strengthen its position in this emerging main business [3]

证券代码：002172 证券简称：澳洋科技 江苏澳洋科技股份有限公司投资者关系活动记录表 编号：2015-01 | --- | --- | --- | |----------------|--------------------------------|------------------------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 通金投资 陈坤、国信证券 苏淼、华安基金 袁银泉、中国人寿资 | | 人员姓名 | | 管 赵文龙、国海富兰克林基金 张琼钢、兴业证券 郑方镳 李鸣 | | | | 孙佳丽、细水投资 刘伟、鸿道投资 应振洲、农银汇理基金 徐治 | | | | 彪 陈继业、华安基金 周阳、中银基金 王帅、东吴人寿 张亚辉、 | | | | 汇添富基金 李华伟、东方资管 周云 蔡志鹏 ...

证券代码：002172 证券简称：澳洋科技 江苏澳洋科技股份有限公司投资者关系活动记录表 编号：2016-02 | --- | --- | --- | |-----------------------|-------------------------|---------------------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中金公司 高峥、唐卓菁；申万宏源 何婧雯、张颢译；国海证 | | | | 券 梁欢；华创证券 蔡春根；大成基金 李博、韩创；银华基金 | | 人员姓名 | 王丽敏。 | | | 时间 | 2016 年 2 月 18 | 日 | | 地点 | | 江苏澳洋科技股份有限公司会议室 | | 上市公司接待人 员姓名 | 马科文、季超 | | | 投资者关系活动 | 一、粘胶短纤 ...

Group 1: Viscose Staple Fiber Business - The market outlook for the viscose market is optimistic, with the Xinjiang production base returning to normal operations, which helps stabilize the profitability of viscose staple fiber by reducing cyclical fluctuations [3]. Group 2: Health Industry Development - The company has established a medical service system centered around Aoyang Hospital, with branches including Yangshe, Sanxing, and Shunkang, focusing on basic medical services while incorporating specialized features [3]. - Aoyang Hospital is a JCI accredited facility and was recognized as "2015 National Excellent Private Hospital" and "2015 Most Valuable Private Hospital" [3]. - The company aims to accelerate brand development in the health sector, enhance specialized departments, and improve the competitiveness in the East China region while advancing the construction of an information-based medical platform [3]. - In the pharmaceutical distribution sector, Aoyang Health has developed a large modern pharmaceutical distribution network covering East China and serving the entire country, becoming one of the largest private pharmaceutical logistics enterprises in the region [3]. - The implementation of a private placement will support the development of the health industry, enhance the technical level of medical services, and facilitate the company's expansion beyond Zhangjiagang into a chain operation model [3].

江苏澳洋健康产业股份有限公司 2022 年第三季度报告 证券代码：002172 证券简称：澳洋健康 公告编号：2022-52 江苏澳洋健康产业股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 1 江苏澳洋健康产业股份有限公司 2022 年第三季度报告 （二） 非经常性损益项目和金额 适用 □不适用 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元 ...

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥1.035 billion, a decrease of 41.49% compared to the same period last year[20]. - The net profit attributable to shareholders was approximately ¥46.03 million, a significant turnaround from a loss of ¥765.12 million in the previous year, representing a 106.02% increase[20]. - The net cash flow from operating activities was negative at approximately -¥201.05 million, a decline of 530.82% compared to the previous year[20]. - Basic and diluted earnings per share were both ¥0.06, compared to -¥0.99 in the same period last year, marking a 106.06% improvement[20]. - The weighted average return on equity was 53.41%, a substantial increase of 187.69% from -134.28% in the previous year[20]. - Total assets at the end of the reporting period were approximately ¥2.979 billion, down 22.09% from the end of the previous year[20]. - The net assets attributable to shareholders increased by 72.88% to approximately ¥109.18 million compared to the previous year[20]. - The company achieved a revenue of approximately CNY 1.04 billion, a decrease of 41.49% compared to the previous year's CNY 1.77 billion, primarily due to the termination of the chemical fiber business[40]. - Operating costs decreased by 44.00% to CNY 906.17 million, reflecting the cessation of the chemical fiber operations[40]. - The company reported a net cash inflow from investment activities of CNY 864.39 million, a significant increase of 189.41% due to proceeds from the sale of chemical fiber assets[40]. Business Transformation - The company has fully transformed its main business to health services, with a focus on medical services that have strong anti-cyclical properties[28]. - The company completed the sale of all assets related to differentiated viscose short fibers and ordinary viscose fibers, marking a full transition to the health industry[38]. - The company is focusing on transforming its business towards the medical health sector, aiming for business transformation and industrial upgrading[68]. - The company plans to explore integrated medical and rehabilitation services following the merger of the Port City Rehabilitation Hospital with Aoyang Hospital[61]. - The company has established Jiangsu Aoyang Biotechnology Co., Ltd. to explore sales in functional foods and health products, seeking new growth channels[38]. Strategic Initiatives - The company plans to accelerate brand building in the health sector and enhance specialty care cultivation, aiming to strengthen its competitive position in East China[36]. - The company aims to build a high-level research institute that integrates medical, teaching, and research functions, with a focus on oncology[34]. - The company plans to continue expanding its healthcare services and logistics operations as part of its strategic transformation[41]. - The company plans to focus on market expansion and new product development in the upcoming quarters to drive growth[144]. - The company has initiated a strategic partnership with a leading technology firm to enhance its product offerings and improve operational efficiency[160]. Market and Industry Outlook - The company is positioned to benefit from the growing demand for medical services driven by population aging and chronic disease prevalence, with a significant growth potential in the health service industry[32]. - The government policies under the "14th Five-Year Plan" present greater opportunities for the health industry, indicating a favorable environment for the company's continued growth[34]. - Future guidance indicates an expected revenue growth of 20% for the second half of 2022, driven by new product launches and market expansion strategies[160]. Risks and Challenges - The company has acknowledged risks related to national policies affecting the healthcare industry, urging investors to remain aware of investment risks[3]. - The company is facing macroeconomic risks that could impact consumer demand and purchasing power, particularly in the context of a slowing economy[72]. - The company is also addressing competition risks in the healthcare sector, particularly from private hospitals entering the market[72]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[4]. - The total number of shares is 776,481,362, with 10,749,002 shares repurchased, representing 1.38% of total shares[119]. - The largest shareholder, Aoyang Group, holds 30.31% of the shares, totaling 235,349,599 shares, with 66,686,543 shares pledged[122]. Financial Stability - Total liabilities decreased from CNY 3,772,380,051.34 to CNY 2,881,266,113.23, a reduction of approximately 24%[138]. - The company's cash and cash equivalents increased from CNY 982,576,248.53 to CNY 1,139,317,934.85, an increase of about 16%[136]. - The equity attributable to the parent company increased from CNY 63,155,721.88 to CNY 109,182,532.10, an increase of approximately 73%[138]. Social Responsibility - The company has actively engaged in social responsibility initiatives, including free medical consultations in communities[82]. - The company has implemented various public welfare projects, receiving positive feedback from the community[82]. Compliance and Governance - The semi-annual financial report was not audited[88]. - No major litigation or arbitration cases were reported, with a total of 1,852.44 million yuan involved in minor cases[92]. - The company has not encountered any major changes in the use of raised funds, and the overall use of funds is proceeding normally[59].

Financial Performance - The company's revenue for Q1 2022 was ¥643,577,490.50, a decrease of 34.01% compared to ¥975,222,843.19 in the same period last year[3] - Net profit attributable to shareholders was ¥32,498,869.97, down 9.91% from ¥36,074,414.82 year-on-year[3] - The net profit after deducting non-recurring gains and losses surged by 10,665.15% to ¥39,746,660.40 from ¥369,216.19 in the previous year[3] - The company reported a 49.03% decrease in main business income due to the divestiture of fiber assets[8] - Net profit for Q1 2022 was CNY 32,791,964.27, a decline of 10% from CNY 36,334,858.20 in Q1 2021[21] - Earnings per share for Q1 2022 were CNY 0.04, down from CNY 0.05 in Q1 2021[21] Cash Flow - The net cash flow from operating activities was -¥323,103,011.47, a decline of 263.58% compared to ¥197,519,222.99 last year[3] - Cash inflow from operating activities totaled CNY 750,511,190.57, while cash outflow was CNY 1,073,614,202.04, resulting in a significant cash flow deficit[24] - The net cash flow from investment activities was 761,728,828.43 CNY, compared to a negative cash flow of -197,318,455.24 CNY in the previous period[25] - The total cash inflow from financing activities amounted to 981,994,393.90 CNY, while cash outflow for financing activities was 1,297,818,721.03 CNY, resulting in a net cash flow of -315,824,327.13 CNY[25] - The cash and cash equivalents at the end of the period totaled 255,243,824.48 CNY, an increase from the beginning balance of 132,458,055.32 CNY[25] - The net increase in cash and cash equivalents for the period was 122,785,769.16 CNY, contrasting with a decrease of -269,189,358.79 CNY in the previous period[25] Assets and Liabilities - Total assets decreased by 24.60% to ¥2,882,794,247.05 from ¥3,823,219,194.07 at the end of the previous year[3] - The company's total assets decreased from 3,823,219,194.07 CNY at the beginning of the year to 2,882,794,247.05 CNY at the end of the reporting period[16] - Total current liabilities decreased from 3,455,221,028.57 CNY to 2,520,476,148.47 CNY[17] - The total non-current liabilities decreased from 317,159,022.77 CNY to 278,686,991.58 CNY[17] - Shareholders' equity increased by 51.46% to ¥95,654,591.85 from ¥63,155,721.88 at the end of the previous year[3] Shareholder Information - The total number of common shareholders at the end of the reporting period is 76,083[11] - The largest shareholder, Aoyang Group Co., Ltd., holds 30.31% of shares, totaling 235,349,599 shares, with 66,686,547 shares pledged[12] Business Strategy and Operations - The company is undergoing a strategic business transformation by divesting from chemical fiber operations to focus on the medical health sector[13] - The company is actively pursuing market expansion strategies, particularly in the healthcare sector, as part of its business transformation[13] - The company has ongoing research and development efforts in new products and technologies, although specific details were not disclosed in the report[12] Operating Costs - Operating costs decreased by 32.31% year-on-year, attributed to the reduction in costs from the fiber asset divestiture[9] - Total operating costs for Q1 2022 were CNY 651,936,595.48, down 32.5% from CNY 967,477,741.20 year-over-year[19] Other Financial Metrics - The company experienced a 100% decrease in asset disposal income, as no such income was recorded in the current period[9] - The company reported a credit impairment loss of CNY 41,922,470.58, compared to a gain of CNY 2,650,997.33 in the previous year[21] - The company recorded a loss of CNY 142,691.76 from investment activities, compared to a loss of CNY 119,663.24 in the previous year[21] - The company achieved a cash inflow of CNY 950,803,465.62 from the disposal of fixed assets, a significant increase from CNY 76,177,376.75 in the same period last year[24] Audit and Compliance - The company did not conduct an audit for the first quarter report[27]

Financial Performance - The company's operating revenue for 2021 was approximately ¥3.03 billion, a decrease of 1.77% compared to ¥3.08 billion in 2020[20]. - The net profit attributable to shareholders for 2021 was approximately -¥1.04 billion, representing a decline of 126.35% from -¥458.99 million in 2020[20]. - The net cash flow from operating activities for 2021 was -¥33.47 million, a significant decrease of 126.70% compared to ¥125.33 million in 2020[20]. - The total assets at the end of 2021 were approximately ¥3.82 billion, a decrease of 40.51% from ¥6.43 billion at the end of 2020[20]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥63.16 million, down 93.37% from ¥952.33 million at the end of 2020[20]. - The basic earnings per share for 2021 was -¥1.34, a decline of 127.12% compared to -¥0.59 in 2020[20]. - The weighted average return on net assets for 2021 was -240.00%, a decrease of 201.16% from -38.84% in 2020[20]. - The company reported a total revenue of 1,940.1 million RMB for the year 2021, with a significant increase of 25.39% compared to the previous year[156]. Business Strategy and Focus - The company is in the process of divesting its assets related to the production and sales of differentiated viscose short fibers and ordinary viscose fibers, focusing fully on the healthcare business thereafter[19]. - The company aims to optimize asset adjustments and achieve upgrades in the health industry, focusing on the integration of medical and health services[84]. - The company plans to explore the "light medical beauty" business and expand its coverage in the medical beauty sector[84]. - The company is focused on expanding its healthcare services and product offerings in the market[99]. - The company aims to enhance its brand in the healthcare sector and expand its specialty services, focusing on building a competitive edge in the East China region[40]. Market and Industry Trends - The healthcare industry in China is experiencing rapid growth, driven by increased medical consumption demand and a rising elderly population, with 18.17% of the population aged 60 and above as of 2020[32][33]. - The average annual increase in chronic disease cases in China has reached nearly double over the past decade, significantly boosting the demand for medical services[33]. - The company is positioned to benefit from national policies encouraging private healthcare investment, which aim to enhance the quality and efficiency of medical services[34]. Revenue Segmentation - The medical services segment generated revenue of approximately CNY 948.12 million, representing a growth of 10.54% from CNY 857.69 million in 2020, accounting for 31.30% of total revenue[46]. - The pharmaceutical logistics segment contributed approximately CNY 1.03 billion, a slight increase of 1.58% from CNY 1.01 billion in 2020, making up 33.92% of total revenue[46]. - The chemical fiber segment saw a revenue decline of 13.25%, with total revenue of approximately CNY 1.05 billion compared to CNY 1.21 billion in 2020, representing 34.78% of total revenue[46]. Operational Efficiency - Operating cash inflow increased by 15.83% to ¥2,945,927,809.34, while operating cash outflow rose by 23.22% to ¥2,979,393,388.92[59]. - The company has established a modernized pharmaceutical distribution network covering East China, positioning itself as one of the largest private logistics enterprises in the region[42]. - The new logistics center is designed to meet annual storage and logistics service needs of approximately CNY 2 to 2.5 billion, enhancing operational efficiency and service quality[39][42]. Governance and Management - The company has established a governance structure in compliance with relevant laws and regulations, ensuring independent operations from its controlling shareholder[92]. - The company is committed to risk management and ensuring legal and efficient operations during its transformation[84]. - The company has implemented a comprehensive information disclosure and investor relations management system to ensure transparency[90]. - The company reported a total of 1,153,840 shares held by its directors and supervisors at the beginning of the reporting period[96]. Environmental Responsibility - The company has a daily wastewater treatment capacity of 60,000 tons, with treated water meeting the national discharge standards[134]. - The company has implemented all pollution prevention facilities, with stable operation of wastewater and exhaust gas treatment systems[132]. - The company has established an emergency response plan for environmental incidents, effective from January 8, 2020[133]. Legal and Compliance - The current auditor is Lixin Certified Public Accountants with an audit fee of 1.5 million CNY, and they have been serving for 7 years[145]. - The company has not reported any major deficiencies in non-financial reporting during the reporting period[126]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[157]. Future Outlook - The company provided a positive outlook for the next quarter, projecting a revenue increase of 10% to 1.32 billion RMB[103]. - New product launches are expected to contribute an additional 200 million RMB in revenue over the next fiscal year[103]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB for potential deals[103].

Financial Performance - The company's revenue for Q3 2021 was CNY 660,587,909, a decrease of 15.79% compared to the same period last year[3]. - The net profit attributable to shareholders was a loss of CNY 145,945,060.70, down 51.95% year-on-year[3]. - Total profit decreased by 374.4% year-on-year, primarily due to impairment provisions related to the sale of viscose-related asset groups[8]. - Net profit attributable to the parent company decreased by 345.58% year-on-year, driven by increased impairment provisions from asset sales[8]. - Net loss for Q3 2021 amounted to ¥935,289,063.97, compared to a net loss of ¥213,990,094.33 in Q3 2020, indicating a significant decline in profitability[20]. - The total comprehensive income for the period was -911,062,744.47 CNY, compared to -204,465,903.76 CNY in the previous period, indicating a significant decline[21]. - Basic and diluted earnings per share were both -1.17 CNY, down from -0.26 CNY in the same period last year[21]. Cash Flow - The net cash flow from operating activities was negative CNY 275,502,278.35, representing a decline of 1,213.21% compared to the previous year[3]. - Cash received from sales of goods and services increased by 46.16% year-on-year, attributed to higher sales volume and prices of viscose products[8]. - Cash paid for purchasing goods and services increased by 99.32% year-on-year, due to a rise in cash payments for raw material procurement[8]. - Cash inflow from operating activities totaled 2,192,959,888.41 CNY, an increase from 1,609,782,565.62 CNY in the previous period[24]. - The total cash outflow from operating activities was 2,468,462,166.76 CNY, compared to 1,585,034,183.39 CNY in the previous period[24]. - Cash flow from investing activities generated a net inflow of 163,518,335.51 CNY, compared to a net outflow of -200,524,727.94 CNY in the previous period[24]. - Cash flow from financing activities resulted in a net inflow of 79,504,251.23 CNY, down from 135,102,131.89 CNY in the previous year[25]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,312,266,850.85, a decrease of 17.34% from the end of the previous year[3]. - Total current assets increased to ¥4,291,155,642.53 as of September 30, 2021, from ¥2,876,325,243.35 at the end of 2020, reflecting a growth of 49.2%[15]. - Total liabilities decreased to ¥5,279,253,409.20 from ¥5,458,300,814.89, a reduction of 3.3%[16]. - The company's equity totaled CNY 968,302,505.62, with a capital reserve of CNY 1,151,303,231.24 and retained earnings showing a deficit of CNY 968,394,932.52[29]. - Total assets amounted to CNY 6,426,603,320.51, with current assets at CNY 2,876,325,243.35 and non-current assets at CNY 3,550,278,077.16[28]. Expenses - Other business income increased by 68.06% year-on-year, attributed to higher sales of raw materials and by-products[7]. - Other business costs rose by 126.12% year-on-year, also due to increased sales of raw materials and by-products[7]. - Research and development expenses were reported as zero for the current period, indicating no R&D activities[7]. - The company reported a significant increase in management expenses to ¥241,353,491.34, up from ¥200,849,323.32, reflecting a rise of 20.2%[20]. - Operating profit decreased by 194.93% year-on-year, mainly due to increased asset impairment provisions[8]. Impairment and Provisions - Asset impairment losses increased by 5624.44% year-on-year, primarily due to higher provisions for inventory and fixed assets[8]. - The company experienced a 3160.72% increase in advance receipts, reflecting pre-sales of certain assets during the reporting period[7]. - Investment income decreased by 100.62% compared to the same period last year, mainly due to a reduction in financial management income[8]. Other Information - The company did not undergo an audit for the third quarter report[31]. - The report indicates a significant investment in fixed assets, totaling CNY 3,267,306,561.25, with a decrease of CNY 166,175,115.23 compared to the previous period[28]. - The report was released on October 28, 2021, and is the first to apply the new leasing standards retrospectively[30].